Compounded weight-loss medications such as those promoted in the Hims & Hers commercial aren’t approved by the Food and Drug ...

Medically reviewed by Alex Yampolsky, PharmD Hydroxyzine, whose brand names include Atarax and Vistaril, and Benadryl, the ...

ANI Pharmaceuticals offers an asymmetric opportunity in small-cap pharma, with a niche in generics, rare disease treatments, ...

The FDA has made some modest efforts, but it needs an internal organization that understands and would be an aggressive ...

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

Pursuing dangerous Medicaid block grant schemes and allowing flagrant violations of unequivocal state laws looks like ...

BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...

The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide medications aren't FDA-approved.

The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment of migraine with or without aura in adults.

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...